Aethlon, North Immunology Plan Merger, $180M Financing
Aethlon, North Immunology Plan Merger, $180M Financing
Anonymous
Key Points
1
NOR-101 demonstrated an approximately 42-day half-life in a non-human primate pharmacokinetic study, according to North Immunology.
2
North Immunology plans to rapidly initiate Phase 1b and Phase 2b atopic dermatitis studies during 2027, with topline data from both trials expected in 2028.
3
The financing was backed by healthcare-focused institutional investors including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, and Farallon Capital Management funds.
4
Aethlon’s shares rose more than 470% following the merger and financing announcement, highlighting the immediate market reaction to the proposed transaction.
5
Before the announcement, Aethlon had a market capitalization of roughly $1 million, a current ratio above 5 and minimal debt, but its GF Score was 19 out of 100 and its price-to-sales ratio was near zero versus a historical median of approximately 11.5 times.
Aethlon Medical and North Immunology agreed to merge in an all-stock deal that will reshape the combined company around North's lead drug, NOR-101. The deal includes a $180 million oversubscribed private placement to fund operations through mid-2028, with North shareholders set to own roughly 95% of the merged entity Gibson Dunn. Aethlon shares soared more than 470% on the announcement, reflecting investor enthusiasm for North's experimental antibody treatment for atopic dermatitis and other immune diseases.
NOR-101 Shows Long Half-Life in Early Testing
North Immunology's lead candidate, NOR-101, is a bispecific antibody designed to target both IL-13 and IL-18 pathways. In a non-human primate pharmacokinetic study, the drug showed an approximately 42-day half-life pulse2.com, meaning it stays active in the body much longer than typical biologics. This extended half-life could allow for less frequent dosing, potentially improving patient compliance and treatment outcomes Procopio.
Clinical Timeline Accelerates Through 2027 and 2028
The merger unlocks a rapid development pathway for NOR-101. North plans to start a Phase 1a trial in early 2027, with interim safety and pharmacokinetic data due by midyear Gibson Dunn. The company will then kick off Phase 1b and Phase 2b atopic dermatitis studies later in 2027, with topline data from both trials expected in 2028 pulse2.com. This compressed timeline positions the drug for potential market entry within three to four years.
Heavy-Hitter Investors Back the $180 Million Round
The financing drew support from top-tier healthcare investors including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, and Farallon Capital Management pulse2.com. The round was oversubscribed, meaning demand exceeded available shares, a sign of strong confidence in North's pipeline and the merged company's direction. Roughly $34 million of the $180 million total came from converting North's existing convertible notes.
Aethlon Shareholders Get Minority Stake and Future Upside
Aethlon shareholders will retain about 4.75% of the combined company and receive contingent value rights tied to possible future sales of Aethlon's Hemopurifier business Gibson Dunn. Before the deal, Aethlon had a market cap of roughly $1 million and minimal debt, but struggled with weak fundamentals. The company's GF Score was 19 out of 100 and its price-to-sales ratio was near zero, far below its historical median of 11.5 times rttnews.com. The merger essentially gives Aethlon a second life through North's more advanced drug pipeline.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
18
Articles
20
Reach
38
A
AnonymousAuthor
